Devoleping a novel anti-angiogenic therapy focused on placental growth factor secreted by ovarian cancer cells
Project/Area Number |
24592515
|
Research Category |
Grant-in-Aid for Scientific Research (C)
|
Allocation Type | Multi-year Fund |
Section | 一般 |
Research Field |
Obstetrics and gynecology
|
Research Institution | Osaka University |
Principal Investigator |
|
Co-Investigator(Kenkyū-buntansha) |
SAWADA Kenjiro 大阪大学, 医学系研究科, 講師 (00452392)
MABUCHI Seiji 大阪大学, 医学系研究科, 助教 (00452441)
ISOBE Aki 大阪大学, 医学系研究科, 助教 (60397619)
HASHIMOTO Kae 大阪大学, 医学系研究科, 助教 (90612078)
|
Project Period (FY) |
2012-04-01 – 2015-03-31
|
Project Status |
Completed (Fiscal Year 2014)
|
Budget Amount *help |
¥5,330,000 (Direct Cost: ¥4,100,000、Indirect Cost: ¥1,230,000)
Fiscal Year 2014: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2013: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
Fiscal Year 2012: ¥2,080,000 (Direct Cost: ¥1,600,000、Indirect Cost: ¥480,000)
|
Keywords | 卵巣癌 / 抗血管新生療法 / NF-κB シグナル / VEGF / 抗血管新生治療 / 分子標的治療 / NF-κBシグナル / PlGF |
Outline of Final Research Achievements |
The improvement of outcome in patients with ovarian cancer by an anti-angiogenic therapy has been shown in large clinical trials. However, the only option currently available is the anti-VEGF-A antibody, which efficacy is limited. Therefore, we aim to develop a new anti-angiogenic drug for ovarian cancer. As NF-κB signaling has the potential to regulate several angiogenic factors including VEGF-A, we determined to identify the significance of NF-κB activation in ovarian cancer and to investigate the possibility of a novel NF-κB inhibitor as an anti-angiogenic drug. Immunohistochemical analyses using ovarian cancer tissues showed that NF-κB activation is an independent prognostic factor. A specific NF-κB inhibitor led to the inhibition of angiogenesis in vitro and in vivo. In a xenograft model, the treatment of NF-κB inhibitor significantly suppressed peritoneal dissemination. Anti-angiogenic therapy targeting NF-κB signaling is a potential future option to treat ovarian cancer.
|
Report
(4 results)
Research Products
(18 results)
-
[Journal Article] IKKβ Regulates VEGF Expression and Is a Potential Therapeutic Target for Ovarian Cancer as an Anti-angiogenic Treatment2015
Author(s)
Kinose, Y. Sawada, K. Makino, H. Ogura, T. Mizuno, T. Suzuki, N. Fujikawa, T. Morii, E. Nakamura, K. Sawada, I. Toda, A. Hashimoto, K. Isobe, A. Mabuchi, S. Ohta, T. Itai, A. Morishige, K. I. Kurachi, H. Kimura, T
-
Journal Title
Mol Cancer Ther
Volume: 14
Pages: 909-19
DOI
Related Report
Peer Reviewed / Open Access
-
[Journal Article] The hypoxia-related microRNA miR-199a-3p displays tumor suppressor functions in ovarian carcinoma2015
Author(s)
Kinose, Y. Sawada, K. Nakamura, K. Sawada, I. Toda, A. Nakatsuka, E. Hashimoto, K. Mabuchi, S. Takahashi, K. Kurachi, H. Lengyel, E. Kimura, T.
-
Journal Title
Oncotarget
Volume: -
Pages: -
Related Report
Peer Reviewed / Open Access
-
[Journal Article] Estradiol and raloxifene induce the proliferation of osteoblasts through G-protein-coupled receptor GPR302013
Author(s)
Noda-Seino, H. Sawada, K. Hayakawa, J. Ohyagi-Hara, C. Mabuchi, S. Takahashi, K. Nishio, Y. Sakata, M. Kurachi, H. Kimura, T.
-
Journal Title
J Endocrinol Invest
Volume: 36
Pages: 21-7
DOI
Related Report
Peer Reviewed
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-